Background:
Breast cancer remains one of most lethal illnesses and the most common
malignancies among women, making it important to discover novel
biomarkers and therapeutic targets for the disease.
Immunotherapy has become a promising therapeutic tool for
breast cancer. The role of TRIM8 in
breast cancer has rarely been reported. Method: Here we identified TRIM8 expression and its potential function on survival in patients with
breast cancer using TCGA (The
cancer genome atlas), GEO (Gene expression omnibus) database and METABRIC (Molecular Taxonomy of
Breast Cancer International Consortium). Then, TIMER and TISIDB databases were used to investigate the correlations between TRIM8
mRNA levels and immune characteristics. Using stepwise cox regression, we established an immune prognostic signature based on five differentially expression immune-related genes (DE-IRGs). Finally, a nomogram, accompanied by a calibration curve was proposed to predict 1-, 3-, and 5-year survival for
breast cancer patients. Results: We found that TRIM8 expression was dramatically lower in
breast cancer tissues in comparison with normal tissues. Lower TRIM8 expression was related with worse prognosis in
breast cancer. TIMER and TISIDB analysis showed that there were strong correlations between TRIM8 expression and immune characteristics. The receiver operating characteristic (ROC) curve confirmed the good performance in survival prediction and showed good accuracy of the immune prognostic signature. We demonstrated the model usefulness of predictions by nomogram and calibration curves. Our findings indicated that TRIM8 might be a potential link between progression and prognosis survival of
breast cancer. Conclusion: This is a comprehensive study to reveal that tripartite motif 8 (TRIM8) may serve as a potential prognostic
biomarker associating with immune characteristics and provide a novel therapeutic target for the treatment of
breast cancer.